These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 31200358)

  • 1. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
    Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Bartlett NL; Caimi PF; Chang JE; Chavez JC; Christian B; Fayad LE; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Mehta A; Nademanee A; Rabinovitch R; Reddy N; Reid E; Roberts KB; Smith SD; Snyder ED; Swinnen LJ; Vose JM; Dwyer MA; Sundar H
    J Natl Compr Canc Netw; 2019 Jun; 17(6):650-661. PubMed ID: 31200358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T cell therapy for B-cell lymphomas.
    Chavez JC; Locke FL
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CAR-T cells in lymphomas: Current and evolving role].
    Messéant O; Houot R
    Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
    Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
    Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
    Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Andreadis B; Bartlett NL; Budde LE; Caimi PF; Chang JE; Christian B; DeVos S; Dholaria B; Fayad LE; Habermann TM; Hamid MS; Hernandez-Ilizaliturri F; Hu B; Kaminski MS; Karimi Y; Kelsey CR; King R; Krivacic S; LaCasce AS; Lim M; Messmer M; Narkhede M; Rabinovitch R; Ramakrishnan P; Reid E; Roberts KB; Saeed H; Smith SD; Svoboda J; Swinnen LJ; Tuscano J; Vose JM; Dwyer MA; Sundar H
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1118-1131. PubMed ID: 37935098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.
    Boeri M; Purdum AG; Sutphin J; Hauber B; Kaye JA
    Future Oncol; 2021 Dec; 17(34):4697-4709. PubMed ID: 34581197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Aggressive B Cell Lymphomas: Updates in 2019.
    Mondello P; Nowakowski GS
    Curr Hematol Malig Rep; 2020 Jun; 15(3):225-234. PubMed ID: 32372238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma.
    Roschewski M; Phelan JD; Wilson WH
    Cancer J; 2020; 26(3):195-205. PubMed ID: 32496453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances.
    Epperla N; Hamadani M
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):277-284. PubMed ID: 28633038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma.
    Yaniv B; Tanenbaum B; Kazakova V; Patel SA
    Leuk Res; 2024 Jul; 142():107519. PubMed ID: 38761562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T-Cell Therapy.
    Ogba N; Arwood NM; Bartlett NL; Bloom M; Brown P; Brown C; Budde EL; Carlson R; Farnia S; Fry TJ; Garber M; Gardner RA; Gurschick L; Kropf P; Reitan JJ; Sauter C; Shah B; Shpall EJ; Rosen ST
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1092-1106. PubMed ID: 30181421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
    Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
    N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
    N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.